Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.
Anna T. Levy, DO
Advertisement
Articles by Anna T. Levy, DO
Anna T. Levy, DO, discuses future research directions for lenvatinib in patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCCPublished: April 9th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5